Allegro Medical Innovations

Allegro Ophthalmics is a clinical-stage biotechnology company focused on developing novel therapies for vitreoretinal diseases. The company's primary platform is based on integrin peptide therapy, which targets multiple pathways of vision loss, including oxidative stress, inflammation, and vascular leakage. Its lead candidate, risuteganib (Luminate), is a first-in-class integrin peptide currently in Phase 2 development for the treatment of dry age-related macular degeneration (Dry AMD). Allegro's approach aims to provide a more durable and effective alternative to current anti-VEGF treatments by addressing the underlying cellular dysfunction in the retina.